Evidence map›Paper›PMID 38652938›Full record

ArticleJournal of pharmaceutical and biomedical analysis2024

A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.

Elizabeth Challenger, Sujan Dilly-Penchala, Colin Hale, Richard Fitzgerald, Helen Reynolds, Justin Chiong, Tim Rowland, Tom Fletcher, Saye Khoo, Laura Else

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Elizabeth ChallengerDepartment of Pharmacology and Therapeutics, Institute of Systems and Molecular Biology, University of Liverpool, Liverpool L7 8TX, UK. Electronic address: echall@liverpool.ac.uk.
Sujan Dilly-PenchalaDepartment of Pharmacology and Therapeutics, Institute of Systems and Molecular Biology, University of Liverpool, Liverpool L7 8TX, UK.
Colin HaleLiverpool University Hospitals NHS Foundation Trust, Prescot Street, Liverpool L7 8XP, UK.
Richard FitzgeraldLiverpool University Hospitals NHS Foundation Trust, Prescot Street, Liverpool L7 8XP, UK.
Helen ReynoldsDepartment of Pharmacology and Therapeutics, Institute of Systems and Molecular Biology, University of Liverpool, Liverpool L7 8TX, UK.
Justin ChiongDepartment of Pharmacology and Therapeutics, Institute of Systems and Molecular Biology, University of Liverpool, Liverpool L7 8TX, UK.
Tim RowlandLiverpool University Hospitals NHS Foundation Trust, Prescot Street, Liverpool L7 8XP, UK.
Tom FletcherLiverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
Saye KhooDepartment of Pharmacology and Therapeutics, Institute of Systems and Molecular Biology, University of Liverpool, Liverpool L7 8TX, UK; Liverpool University Hospitals NHS Foundation Trust, Prescot Street, Liverpool L7 8XP, UK.
Laura ElseDepartment of Pharmacology and Therapeutics, Institute of Systems and Molecular Biology, University of Liverpool, Liverpool L7 8TX, UK.
University of Liverpool · GBAintree University Hospitals NHS Foundation Trust · GBLiverpool School of Tropical Medicine · GB

Funding

Wellcome Trust 221590
6 · The paper itself

Abstract

Favipiravir is a broad-spectrum antiviral that is metabolised intracellularly into the active form, favipiravir ribofuranosyl-5'-triphosphate (F-RTP). Measurement of the intracellular concentration of F-RTP in mononuclear cells is a crucial step to characterising the pharmacokinetics of F-RTP and to enable more appropriate dose selection for the treatment of COVID-19 and emerging infectious diseases. The described method was validated over the range 24 - 2280 pmol/sample. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and lysed using methanol-water (70:30, v/v) before cellular components were precipitated with acetonitrile and the supernatant further cleaned by weak anion exchange solid phase extraction. The method was found to be both precise and accurate and was successfully utilised to analyse F-RTP concentrations in patient samples collected as part of the AGILE CST-6 clinical trial.

Indexed as

AmidesAntiviral AgentsLeukocytes, MononuclearPyrazinesCOVID-19COVID-19 Drug TreatmentHumansLiquid Chromatography-Mass SpectrometryReproducibility of ResultsSARS-CoV-2Solid Phase ExtractionTandem Mass SpectrometryAmidesAntiviral AgentsfavipiravirPyrazinesBioanalysisCOVID-19Favipiravir RTPSARS-CoV-2T-705 RTP

Identifiers

PMID38652938
PMCPMC7617887
OpenAlexW4394985069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.